EP0263761A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Non-A, non-B, hepatitis antigen
Assignee: Ono Yasushi
•
Filing: 1987-10-07
•
Granted: —
•
Expires: 2007-10-07
Abstract
Abstract The present invention relates to purified non-A, non-B hepatitis antigens, which have a molecular weight of 44,000 ± 2,000 and a partial amino acid sequence represented by any of the formulae: (I) Tyr-Asn-Ser-Pro-Thr-Asn-Phe-Gln-Ile-Asp-Gly-Arg-Asn-Arg-Lys; (II) Val-Ile-Met-Asp-Leu-Lys; (III) Ser-Ser-Phe-Phe-Asn-Ser-Val-Arg-Ser-Val-Phe-Gln-Gly-His-Val.
Inventors
- 👤 Toshio Shikata
- 👤 Yasushi Ono
- 👤 Yohko Shimizu
- 👤 Ei Yamada
- 👤 Yoshikazu Honda
- 👤 Jun Kondo
- 👤 Toshirou Maeda
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-31 09:35
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; C07K14/01; C07K14/02; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/576; G01N33/5767; A; A61; A61K; A61K39/00; A61K39/12; A61K39/29; C07K1/00; C07K1/14
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
34 words
A purified non-A, non-B hepatitis antigen, which has a molecular weight of 44,000 ± 2,000 and a partial amino acid sequence representend by any of the formulae : (I) Tyr-Asn-Ser-Pro-Thr-Asn-Phe-Gln-Ile-Asp-Gly-Arg-Asn-Arg-Lys; (II) Val-Ile-Met-Asp-Leu-Lys; (III) Ser-Ser-Phe-Phe-Asn-Ser-Val-Arg-Ser-Val-Phe-Gln-Gly-His-Val.
Claim 2
Dependent Claim
34 words
A purified non-A, non-B hepatitis antigen, which has a molecular weight of 44,000 ± 2,000 and a partial amino acid sequence representend by any of the formulae : (I) Tyr-Asn-Ser-Pro-Thr-Asn-Phe-Gln-Ile-Asp-Gly-Arg-Asn-Arg-Lys; (II) Val-Ile-Met-Asp-Leu-Lys; (III) Ser-Ser-Phe-Phe-Asn-Ser-Val-Arg-Ser-Val-Phe-Gln-Gly-His-Val.
Claim 3
Dependent Claim
47 words
Antigen according to claim 1,characterized by the fact it reacts with mouse specific antibody, it has a molecular weight in the range of from 42,000 to 46,000 (44,000 ± 2,000) and an isoelectric point (pH) in the range of from 6.8 ± 0.5 to 7.2 ± 0.5.
Claim 4
Dependent Claim
40 words
Antigen according to claim 1 or 2, characterized by the fact that the materials obtained by digesting the antigen with lysyl endopeptidase have an elution pattern on the reversed phase high performance liquid chromatography as shown on the sole figure.
Claim 5
Dependent Claim
37 words
A process for preparing a purified non-A, non-B hepatitis antigen, which has a molecular weight of 44,000 2,000 and a partial amino acid sequence represented by any of the formulae : (I) Tyr-Asn-Ser-Pro-Thr-Asn-Phe-Gln-Ile-Asp-Gly-Arg-Asn-Arg-Lys; (II) Val-Ile-Met-Asp-Leu-Lys; (III) Ser-Ser-Phe-Phe-Asn-Ser-Val-Arg-Ser-Val-Phe-Gln-Gly-His-Val.
Claim 6
Dependent Claim
37 words
A process for preparing a purified non-A, non-B hepatitis antigen, which has a molecular weight of 44,000 2,000 and a partial amino acid sequence represented by any of the formulae : (I) Tyr-Asn-Ser-Pro-Thr-Asn-Phe-Gln-Ile-Asp-Gly-Arg-Asn-Arg-Lys; (II) Val-Ile-Met-Asp-Leu-Lys; (III) Ser-Ser-Phe-Phe-Asn-Ser-Val-Arg-Ser-Val-Phe-Gln-Gly-His-Val.
Claim 7
Dependent Claim
66 words
said process comprising homogenizing a liver specimen from a human or chimpanzee individual with non-A, non-B hepatitis, centrifuging the homogenized materials, subjecting the supernatant to sucrose cushion ultra centrifugation, subjecting the resulting precipitate to sucrose density gradient ultra centrifugation, ultra centrifuging a desired fraction, electrophoresing the precipitate on SDS-polyacrylamide gel, and extracting a protein from the gel corresponding to a molecular weight of 44,000 ± 2,000.
Claim 8
Dependent Claim
66 words
said process comprising homogenizing a liver specimen from a human or chimpanzee individual with non-A, non-B hepatitis, centrifuging the homogenized materials, subjecting the supernatant to sucrose cushion ultra centrifugation, subjecting the resulting precipitate to sucrose density gradient ultra centrifugation, ultra centrifuging a desired fraction, electrophoresing the precipitate on SDS-polyacrylamide gel, and extracting a protein from the gel corresponding to a molecular weight of 44,000 ± 2,000.
Claim 9
Dependent Claim
165 words
The process of claim 4 comprising homogenizing a liver specimen from a human or chimpanzee individual with non-A, non-B hepatitis, at about 10.000 g for a period of from about 30 minutes to one hour, placing the resultant supernatant on a buffer containing 15-25% (W/W) sucrose in a centrifugal tube and centrifuging at about 100,000 × g for about 3 to 5 hours to purify, dissolving the pellet in a small amount of a buffer and subjecting to sucrose density gradient centrifugation to further purify, collecting a fraction corresponding to a sucrose density in the range of from about 1.20 to 1.25, further centrifuging said fraction at 100,000 × g for about 3 to 5 hours, dissolving the pellet in a small amount of a buffer and subjecting to 0.1% SDS (sodium dodecyl sulfate solution)/7-15% polyacrylamide gel electrophoresis at a constant current of 5 to 30 mA for a period of from 45 minutes to 6 hours and extracting the desired protein from the gel.
Claim 10
Dependent Claim
26 words
The process of claim 5.wherein the centrifugation is carried out in 10-60% (W/W) sucrose density gradient at 70,000-80,000 × g for about 50 to 60 hours.
Claim 11
Independent Claim
24 words
A method for the in vitro diagnostic for non-A, non-B hepatitis,comprising the use of an antigen according to anyone of claims 1 to 3.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.